Apceth GmbH Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic as Part of the m4 Initiative of the Munich Biotech Cluster
2/4/2013 2:00:09 PM
More...
|
Apceth GmbH and Indivumed GmbH to Develop Biomarker Platform for Targeted Cellular Therapies
2/22/2012 8:45:20 AM
More...
|
Apceth GmbH und Co. KG Received Extended Manufacturer's Licence for Somatic Cell Therapeutics at the Ottobrunn Site
10/31/2011 9:33:14 AM
More...
|